The third-generation bisphosphonates inhibit proliferation of murine osteosarcoma cells with induction of apoptosis

• Published in: Cancer letters Vol. 238; no. 1; pp. 111 - 118
• Main Authors: Horie, Naoyuki, Murata, Hiroaki, Nishigaki, Yasunori, Matsui, Takaaki, Segawa, Hidekazu, Nogawa, Masaki, Yuasa, Takeshi, Kimura, Shinya, Maekawa, Taira, Fushiki, Shinji, Kubo, Toshikazu
• Format: Journal Article
• Language: English
• Published: Ireland Elsevier Ireland Ltd 08.07.2006; Elsevier Limited
• Subjects: Animals; Apoptosis; Apoptosis - drug effects; Bisphosphonates; Bone Density Conservation Agents - therapeutic use; Cancer therapies; Cell culture; Cell Cycle Proteins - drug effects; Cell growth; Cell Line, Tumor; Cell Nucleus - drug effects; Cell Proliferation - drug effects; Diphosphonates - therapeutic use; Disease Models, Animal; Drug resistance; Drug Screening Assays, Antitumor; GTP-Binding Proteins - drug effects; Hydroxyapatite; Imidazoles - therapeutic use; Leukemia; Mice; Nitrogen; Osteosarcoma; Osteosarcoma - drug therapy; P-glycoprotein; Proteins; YM175; YM529; Japan; P-glycoprotein; YM529; YM175; Osteosarcoma; Bisphosphonates; Apoptosis
• ISSN: 0304-3835; 1872-7980
• DOI: 10.1016/j.canlet.2005.06.041

Third generation bisphosphonates (BPs), including YM175 and YM529, are known to inhibit bone resorption. The aim of this study was to evaluate the anti-tumor effects of these drugs on murine osteosarcoma cell lines, in terms of proliferation and apoptosis. We found that both YM175 and YM529 strongly inhibited the in vitro proliferation and induced apoptosis of murine osteosarcoma cells. YM529 was more effective than YM175 in inhibiting cell proliferation. These observations suggest that third-generation BPs directly affect on the proliferation and survival of osteosarcoma cells, which supports the possibility that they could be beneficial in the treatment of osteosarcoma patients.